What diseases can Upatinib be used for? Which patients are suitable for use?

　　Upatinib is an oral small molecule Janus kinase(JAK)inhibitor that has been approved for the treatment of various immune-mediated inflammatory diseases in multiple countries worldwide.Based on international guidelines and real-world research,its clinical application has gradually expanded from the field of rheumatism and immunology to multiple systems such as skin,digestion,and vasculitis,demonstrating multi-target immune regulatory value.

　　Rheumatology and Immunology:Suitable for adult patients with rheumatoid arthritis(RA)who have insufficient response to traditional anti rheumatic drugs(DMARDs)or cannot tolerate biologics;Subsequently expanded to include psoriatic arthritis(PsA),ankylosing spondylitis(AS),and axial spondyloarthritis(axSpA),providing oral targeted regimens for chronic pain and joint dysfunction.

　　Dermatology field:Used for moderate to severe atopic dermatitis(AD):especially for adult and eligible adolescent patients with poor control of external medication or systemic therapy.It has clinical value in relieving itching and improving skin lesions,and strict evaluation of infection and long-term safety is required.

　　In the field of digestive system:it has been approved for use in moderate to severe ulcerative colitis(UC)and Crohn's disease(CD),providing a new oral treatment option for patients with inflammatory bowel disease who have poor response to traditional therapies.

　　Other progress:We have also accumulated application experience in systemic inflammatory diseases such as giant cell arteritis(GCA)and polyarthrosis juvenile idiopathic arthritis(pJIA).The use of drugs in children and adolescents requires a comprehensive evaluation of safety factors such as growth and development,infection risk,etc.by a specialist physician.

　　Overall,Upatinib is mainly targeted at adult patients with moderate to severe immune inflammatory diseases,limited efficacy of traditional treatments,and poor adherence to oral administration or injection.Clinical application should strictly follow the principle of individualization and continuously pay attention to the dynamic updates of safety data and indications.